Health Care Equipment

TransMedics

TransMedics released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 173.93 M (forecast USD 174.06 M), actual EPS USD 0.2 (forecast USD 0.5842)

TransMedics Group reports Q1 earnings

TransMedics to Release FY2026 Q1 Earnings on May 5 After-Market EST, Forecast Revenue USD 174.06 M, EPS USD 0.5842

TransMedics released FY2025 earnings on February 24 After-Market EST, actual revenue USD 605.49 M (forecast USD 600.5 M), actual EPS USD 4.8735 (forecast USD 2.565)

TransMedics released FY2025 Q4 earnings on February 24 After-Market EST, actual revenue USD 160.76 M (forecast USD 155.28 M), actual EPS USD 2.5726 (forecast USD 0.3551)

TransMedics to release FY2025 Q4 earnings on February 24 After-Market EST, forecast revenue USD 155.28 M, EPS USD 0.3634

TransMedics Releases Presentation on Innovative Organ Care System

TransMedics Leases 498,000 Square Feet in Assembly Innovation Park

Piper Sandler Analyst Reiterates Buy Rating on TransMedics Group

Canaccord Genuity Raises TransMedics' Target Price to $148

Canaccord Genuity Analyst Maintains Buy Rating on TransMedics Group

TransMedics Director David Weill Disposes of Company Common Stock

William Blair Analyst Maintains Buy Rating on TransMedics Group

TransMedics Executives Sell $435,660 in Stock

TransMedics Group Inc. Official Disposes of Common Stock

TransMedics CEO and President Acquires Common Stock

Advisors Preferred LLC Increased Holdings of TransMedics Group Inc. in Q2

Edward M. Basile Reports Disposition of TransMedics Group Inc. Stock

Jennings Maintains Buy Rating on TransMedics Group

TransMedics released FY2025 9 Months earnings on October 29 After-Market (EST), actual revenue USD 444.73 M, actual EPS USD 2.2808

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

TMDX

LABU

SBIO

TransMedics will present at the William Blair 46th Annual Growth Stock Conference in Chicago on June 2, 2026, starting at 2:20 p.m. ET. This announcement was originally published by Transmedics Group Inc. via PR Newswire on May 19, 2026.

PUBT

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

TransMedics presents at William Blair Growth Stock Conference

TransMedics Group (NASDAQ:TMDX) shares rose 7.1% to $67.71, despite a significant drop in trading volume. Analysts have mixed ratings, with target prices ranging from $85 to $190. The company reported a Q1 EPS of $0.30, missing estimates, but revenue increased 21.2% year-over-year. Insiders have sold shares recently, and hedge funds have increased their holdings in the company.

Market Beat

SPDR S&P Health Equip

iShares US Medical Devices

Stifel Financial

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

TransMedics Group (NASDAQ:TMDX) Shares Up 7.1%  - Here's What Happened

TransMedics Group reported Q1 2026 results with revenue of $173.93 million, up from $143.54 million, but net income fell to $7.32 million from $25.68 million. The company reaffirmed its 2026 revenue guidance of $727 million to $757 million, indicating confidence in growth despite margin pressures. Analysts express mixed views on future earnings, highlighting risks associated with rising costs and fluctuating profitability.

Simplywall

Why TransMedics Group (TMDX) Is Down 6.8% After Mixed Q1 Results And Reaffirmed 2026 Guidance

Bridge to Life™ Ltd. announced new data at ILTS 2026 demonstrating that hypothermic oxygenated perfusion (HOPE) with VitaSmart™ enhances the use of marginal donor livers and preserves mitochondrial function for real-time viability assessment. The findings support HOPE's adoption in the U.S. and EU to increase organ availability and reduce transplant wait times. The studies indicate that HOPE improves outcomes for steatotic and older donor livers, reinforcing its clinical and economic justification for broader use in transplant centers. The FDA approval of VitaSmart™ positions Bridge to Life as a leader in HOPE technology for liver transplantation.

prnewswire

Direxion S&P Biotech Bear 3X

06:57 ETBridge to Life presenta nuevos datos en ILTS 2026 sobre HOPE con VitaSmart™

TransMedics Group (NASDAQ:TMDX) has delivered an annualized return of 24.1% over the past 5 years, outperforming the market by 11.88%. An investment of $1000 in TMDX stock five years ago would now be worth $2,971.67, reflecting the significant impact of compounded returns. The company's current market capitalization stands at $2.52 billion.

benzinga_article

If You Invested $1000 In TransMedics Group Stock 5 Years Ago, You Would Have This Much Today

Canaccord Genuity Group has lowered its price target for TransMedics Group (NASDAQ:TMDX) from $152.00 to $124.00 while maintaining a "buy" rating. This new target suggests a potential upside of 70.05% from the current price. Other analysts have also adjusted their ratings, with some lowering targets and others maintaining or changing their ratings. The stock recently traded at $72.92, with a market cap of $2.52 billion. The company reported a revenue of $173.93 million for the last quarter, missing estimates slightly.

Toronto Dominion Bank

JPMorgan Chase

Piper Sandler Cos

ROYAL BANK OF CANADA

Goldman Sachs

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

GS Hldg R

TransMedics Group (NASDAQ:TMDX) Given New $124.00 Price Target at Canaccord Genuity Group

PRIM

KVYO

ATEC

AZTA

NICE

BFAM

Primoris(PRIM) fell 50.11%, with a trading turnover 1.4 Billion USD, and a year-to-date fell 18.4%. Limbach(LMB) fell 32.55%, with a trading turnover 99.0 Million USD, and a year-to-date fell 1.1%. Klaviyo(KVYO) fell 32.23%, with a trading turnover 322.7 Million USD, and a year-to-date fell 51.3%.

Top Gainers&Losers

Primoris

Limbach

Klaviyo

Alphatec

Azenta

NICE-Syst

Bright Horizons Family Solutions

Cencora

Top 10 US Stock Losers (5.6)

TD Cowen has lowered its price target for TransMedics Group (NASDAQ:TMDX) from $190.00 to $120.00 while maintaining a "buy" rating. Other analysts have also adjusted their targets, with Piper Sandler and Needham & Company LLC setting targets at $120.00 and $142.00, respectively. The stock currently trades at $72.87, indicating a potential upside of 64.68% from the new target. The company reported a quarterly EPS of $0.30, missing estimates, and has a market cap of $2.52 billion.

TransMedics Group (NASDAQ:TMDX) Price Target Lowered to $120.00 at TD Cowen

CVGI

SKYX

In Wednesday's trading session, BlueLinx Holdings (NYSE:BXC) saw a significant gain of 28.8%, reaching $59.5, following its Q1 earnings report. Other notable gainers included SKYX Platforms (NASDAQ:SKYX) up 26.38%, Commercial Vehicle Group (NASDAQ:CVGI) up 24.17%, and GEO Group (NYSE:GEO) up 23.31%. Conversely, Primoris Services (NYSE:PRIM) experienced a sharp decline of 50.6% to $100.14, along with Limbach Holdings (NASDAQ:LMB) down 35.14% and Phoenix Asia Holdings (NASDAQ:PHOE) down 33.74%.

TransMedics(TMDX.US)